DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Merck - 1
Top related locs:
Japan Australia
Top related orgs:
Merck - 1 Prometheus Biosciences - 1 Imago BioSciences - 1 Kelun - 1 Biotech - 1 LSEG - 1 U.S - 1

Search resuls for: "Imago BioSciences"


6 mentions found


☆ Merck results beat expectations on strong Keytruda sales, surprise Covid drug growth
  + stars: | 2023-10-26 | by ( Annika Kim Constantino | ) www.cnbc.com   time to read: +2 min
Merck on Thursday reported third-quarter revenue and adjusted earnings that topped expectations on strong sales of its blockbuster cancer drug Keytruda, HPV vaccine Gardasil and surprisingly, its Covid drug Lagevrio. Merck lowered its adjusted profit guidance to $1.33 to $1.38 per share, from a previous forecast of $2.95 to $3.05 a share. But that updated outlook reflects an upfront charge of $5.5 billion, or $1.70 per share, related to the company's recent drug collaboration agreement with Daiichi Sankyo. Excluding Lagevrio, pharmaceutical sales grew 9%. The Covid antiviral treatment brought in $640 million in sales for the quarter, up 47% from the third quarter of 2022.
Persons: Merck Organizations: Merck, Prometheus Biosciences, Imago BioSciences, Kelun, Biotech, LSEG, U.S Locations: Japan, Australia
☆ Pfizer in talks to buy cancer drugmaker Seagen - WSJ
  + stars: | 2023-02-27 | by ( ) www.reuters.com   time to read: +2 min
Feb 27 (Reuters) - Pfizer Inc (PFE.N) is in early-stage talks to acquire cancer drugmaker Seagen Inc (SGEN.O) in a potential multi-billion dollar deal, the Wall Street Journal reported, after advanced discussions between Merck (MRK.N) and Seagen fell through last year. Seagen had a market capitalization of roughly $30 billion, as of Friday's close. Its shares have fallen nearly 10% since July, when the deal talks with Merck were first reported. Pfizer declined to comment on the WSJ report, while Seagen did not immediately respond to a Reuters request for comment. Merck, which bought ADC-maker Imago BioSciences for $1.35 billion in November, is unlikely to show renewed interest in Seagen, analysts said.
☆ Merck Strikes $1.35 Billion Deal for Bone-Marrow Disease Drug Developer
  + stars: | 2022-11-21 | by ( Jonathan D. Rockoff | ) www.wsj.com   time to read: 1 min
Merck has been seeking deals to add fast-growing products and promising drugs in development . Merck & Co. has agreed to buy blood-cancer biotech Imago BioSciences Inc. for $1.35 billion, the big drugmaker’s latest deal in search of new sources of sales. Under the terms, Merck said Monday it will pay $36 a share cash for Imago, which is developing drugs to treat bone-marrow diseases. Merck said it expected the deal to close during the first quarter next year.
☆ Merck to acquire Imago BioSciences for $1.35 bln
  + stars: | 2022-11-21 | by ( Svea Herbst-Bayliss | ) www.reuters.com   time to read: +1 min
Nov 21 (Reuters) - Merck & Co Inc (MRK.N) said on Monday it will acquire cancer drug developer Imago BioSciences Inc (IMGO.O) for a total equity value of $1.35 billion to expand its portfolio of blood disorder treatments. The drugmaker's offer of $36 per share in cash for Imago represents a nearly 107% premium to the company's last close. With Merck's blockbuster cancer immunotherapy Keytruda expected to lose key patents in 2028, the company has been trying to expand its drug portfolio. Imago, which develops drugs for the treatment of bone marrow-related diseases, is currently testing its lead drug bomedemstat for treating a chronic cancer known as myeloproliferative neoplasms. The Imago deal is expected to close in the first quarter of 2023, according to the companies.
☆ Stocks making the biggest moves in the premarket: Walt Disney, Carvana, Coinbase and more
  + stars: | 2022-11-21 | by ( Peter Schacknow | ) www.cnbc.com   time to read: +2 min
Take a look at some of the biggest movers in the premarket:Walt Disney (DIS) – Walt Disney rallied 8.8% in premarket trading after the weekend announcement that former Chairman and CEO Bob Iger is returning as chief executive, replacing Bob Chapek. Carvana (CVNA) – Carvana fell 3.9% in the premarket after The Wall Street Journal quoted analysts as saying the online used car retailer could run out of cash within a year. Coinbase (COIN) – Coinbase slid 6.8% in premarket trading, with the cryptocurrency exchange's shares falling in the wake of rival FTX's bankruptcy. Alibaba (BABA) fell 3.4% in premarket trading, JD.com (JD) dropped 5.3%, Baidu (BIDU) lost 2.7% and Pinduoduo (PDD) slid 2.8%. Williams-Sonoma (WSM) – The housewares retailer's stock fell 1.9% in premarket trading after Barclays downgraded it to "equal weight" from "overweight," pointing to the negative impact of a weakening housing market.
☆ Stocks making the biggest moves midday: Disney, Carvana, Diamondback Energy and more
  + stars: | 2022-11-21 | by ( Tanaya Macheel | ) www.cnbc.com   time to read: +3 min
Disney — Shares jumped 5% after the company reappointed Bob Iger as chief executive officer, effective immediately and 11 months after he left Disney. Carvana — Shares of the used car company slid 13% after Argus downgraded the stock to sell from hold. Energy stocks — Energy stocks were the biggest losers in the S&P 500 midday after oil prices fell to their lowest levels since early January following a Wall Street Journal report that Saudi Arabia and other OPEC oil producers are discussing an output increase. Still, Diamondback Energy and Halliburton fell 4% and 2.9%, respectively. Intel — Shares dipped more than 2% after Cowen downgraded Intel to market perform from outperform, according to StreetAccount.
0 next >>
Total: 6